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Several microbial components, such as bacterial DNA and flagellin, have been used 
as experimental vaccine adjuvants because of their inherent capacity to efficiently 
activate innate immune responses. Likewise, our previous work has shown that the 
major Salmonella Typhi (S. Typhi) outer membrane proteins OmpC and OmpF (porins) 
are highly immunogenic protective antigens that efficiently stimulate innate and adap-
tive immune responses in the absence of exogenous adjuvants. Moreover, S. Typhi 
porins induce the expression of costimulatory molecules on antigen-presenting cells 
through toll-like receptor canonical signaling pathways. However, the potential of major 
S. Typhi porins to be used as vaccine adjuvants remains unknown. Here, we evaluated 
the adjuvant properties of S. Typhi porins against a range of experimental and clini-
cally relevant antigens. Co-immunization of S. Typhi porins with ovalbumin (OVA), an 
otherwise poorly immunogenic antigen, enhanced anti-OVA IgG titers, antibody class 
switching, and affinity maturation. This adjuvant effect was dependent on CD4+ T-cell 
cooperation and was associated with an increase in IFN-γ, IL-17A, and IL-2 production 
by OVA-specific CD4+ T cells. Furthermore, co-immunization of S. Typhi porins with an 
inactivated H1N1 2009 pandemic influenza virus experimental vaccine elicited higher 
hemagglutinating anti-influenza IgG titers, antibody class switching, and affinity matura-
tion. Unexpectedly, co-administration of S. Typhi porins with purified, unconjugated Vi 
Abbreviations: OMP, outer membrane protein; iIAV, inactivated influenza A virus; PorK, proteinase K digested porins; HAU, 
hemagglutinating units; GLA-SE, glucopyranosyl lipid adjuvant-stable emulsion.
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inTrODUcTiOn
Numerous microbial components, such as CpG and flagellin, 
are pathogen-associated molecular patterns (PAMPs) that have 
been used as experimental vaccine adjuvants. Such activities 
reflect their capacity to activate innate immune responses 
through pattern recognition receptors, such as toll-like recep-
tors (TLRs) (1). In addition to these PAMPs, the outer mem-
brane proteins (OMPs, porins) of Gram-negative bacteria have 
also been shown to efficiently activate innate immune responses 
(2, 3). Porins are transport channels that play a key role in 
the diffusion of small molecules and in bacterial homeostasis 
(4). Numerous groups have studied the effects of porins from 
Neisseria (5), Haemophilus (6), Pasteurella (7), Fusobacterium 
(8), Shigella (9, 10), and Salmonella (11–14) on the activation of 
antigen-presenting cells (APCs). Because of the known effects 
that bacterial porins can have on the activation of APCs, some 
of these proteins have been used as potential vaccine adjuvants 
(5, 8, 13–15). The mechanism underlying the adjuvant effect 
of these porins includes events involving both innate and 
adaptive cells. For example, the adjuvant effect of PorB porin 
from Neisseria meningitidis is associated with the upregula-
tion of costimulatory molecules and induction of lymphocyte 
proliferation, MHC-II overexpression, and secretion of pro-
inflammatory cytokines by APCs, mediated mainly by TLR2/1 
ligation (15–18).
Salmonella Typhi expresses multiple porins (19–21). While 
the major S. Typhi OmpC and OmpF porins are expressed 
constitutively, other porins, such as OmpS1 and OmpS2, are 
expressed at low levels under in  vitro culture conditions and 
potentially during infection (22, 23). We have previously shown 
that the major and minor S. Typhi porins are highly immunogenic 
antigens and drive robust responses in the absence of exogenous 
adjuvants (14, 24–28). The major and minor S. Typhi porins can 
efficiently activate the innate immune system through canonical 
TLR2 and TLR4 signaling, resulting in increased costimulatory 
molecules and cytokine expression on dendritic cells (DCs) and 
B cells (12, 14).
Here, we evaluated the potential of the major S. Typhi 
porins to have an adjuvant effect against three distinct types 
of antigens, including ovalbumin (OVA) (a model antigen), 
an inactivated H1N1 2009 pandemic influenza virus, and a Vi 
polysaccharide, T-independent vaccine. These data show that 
porins promoted responses to all three antigens, indicating that 
these proteins may be used as adjuvants to a range of different 
types of antigens.
MaTerials anD MeThODs
ethics statement
All animal procedures were conducted in accordance with 
national guidelines (Norma Oficial Mexicana, NOM-062-ZOO 
1999), following review and approval by the Specialties Hospital 
Ethics Committee of Instituto Mexicano del Seguro Social (IMSS) 
(project number CNIC 2006-785-076).
antigens and immunogens
Endotoxin-free OVA was purchased from Seikagaku 
Corp. (Tokyo, Japan). Pandemic influenza virus (strain A/
Mexico/4482/2009(H1N1)) was grown in chicken embryos 
and kindly provided by the Instituto Nacional de Diagnóstico y 
Referencia Epidemiológicos (InDRE), Mexico City. The virus was 
inactivated using formalin [inactivated influenza A virus (iIAV)] 
and quantified by hemagglutination. For ELISA assays, iIAV was 
concentrated with 6% polyethylene glycol 8000 (Sigma, MO, 
USA) and further purified by centrifugation in a 20–60% sucrose 
density-gradient in NTE Buffer [100 mM NaCl, 10 mM Tris–Cl 
(pH = 7.4), 1 mM EDTA] as described elsewhere (29), and pro-
tein content was quantified by the bicinchoninic acid method.
Porins were purified from S. Typhi ATCC 9993 as previously 
described (12, 27). LPS content was measured using the limulus 
amebocyte lysate assay (Endosafe® KTA; Charles River Endosafe 
Laboratories, Charleston, SC, USA), and all batches tested nega-
tive (detection limit, 0.01 ng LPS/10 μg protein). Digested porins 
(PorK) were prepared with 10 μg of proteinase K (New England 
Biolabs, MA, USA) per 30 μg of porins, followed by overnight 
incubation at 37°C and inactivation of the enzyme at 70°C for 
1 h. LPS from Escherichia coli 0111:B4 was purchased from Sigma 
(MO, USA). Rehydragel was used as an alum control (Reheis, 
NJ, USA). Typhim Vi vaccine was obtained from Sanofi Pasteur 
(Lyon, France).
Mice
Male BALB/c mice (6- to 8-week olds) were purchased from 
Harlan Laboratories (Mexico City, México). DO.11.10 mice 
OVA323–339 transgenic mice were bred at the animal facilities of 
the Experimental Medicine Department, Faculty of Medicine, 
Universidad Nacional Autónoma de México (UNAM).
immunization Protocol
BALB/c mice were immunized i.p. with 100 μg of OVA, 4 hemag-
glutinating units (HAU) of iIAV alone or with 10 μg of major 
S. Typhi porins, 10 μg of proteinase K digested porins, 5 μg of 
capsular polysaccharide vaccine (Vi CPS)—a T-independent antigen—induced higher 
IgG antibody titers and class switching. Together, our results suggest that S. Typhi porins 
OmpC and OmpF are versatile vaccine adjuvants, which could be used to enhance T-cell 
immune responses toward a Th1/Th17 profile, while improving antibody responses to 
otherwise poorly immunogenic T-dependent and T-independent antigens.
Keywords: porins, adjuvants, influenza, Vi polysaccharide, iFn-gamma, il-17, antibody responses
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LPS, or 100 μg alum. Animals were boosted on day 15, and blood 
samples were taken at the indicated time points. For Vi CPS 
experiments, mice were immunized i.p. with 10 μg of Typhim Vi 
CPS vaccine alone or with 10 μg of S. Typhi porins, or proteinase 
K digested porins, with a boost on day 15.
adoptive Transfer and assessment  
of T cell response
A total of 5 ×  106 CFSE-labeled CD4+ T  cells from DO.11.10 
mice were adoptively transferred i.v. After 24  h, mice were 
immunized s.c. in the footpads. Three days after immunization, 
the popliteal lymph nodes were extracted and CD4+ T cells were 
purified by negative selection with Dynabeads® (Thermo Fisher 
Scientific, MA, USA). To assess in vivo T-cell proliferation, CD4+ 
T  cells were stained with PE-conjugated KJ1-26 mAb (against 
DO.11.10 transgenic TCR) and APC-conjugated anti-CD4 (BD 
Biosciences, CA, USA). To determine the cytokine production, 
CD4+ T cells were cocultured at a ratio of 3:1 with splenic DCs 
purified by positive selection from naïve mice. DCs were used 
alone or pulsed with 100 μg of OVA. Then, 24 h after stimulation, 
the supernatants were collected, and the cytokines were quanti-
fied using a Th1/Th2/Th17 CBA kit following the manufacturer’s 
instructions (BD Biosciences, CA, USA). Data were acquired on 
a FACSCalibur (Becton-Dickinson, NJ, USA) and analyzed using 
FlowJo 7.5 software (Tree Star, Stanford, CA, USA).
antibody elisa
High-binding, 96-well polystyrene flat bottom plates (Corning, 
NY, USA) were coated with 15 μg of OVA (Sigma, USA), 1 μg 
of iIAV or 1 μg of Typhim Vi vaccine per well, each dissolved 
in 0.1  M carbonate buffer (pH 9.5). Non-specific binding was 
blocked with 5% non-fat dry milk diluted in PBS pH 7.2. Sera were 
serially diluted twofold and incubated for 1 h at 37°C. Peroxidase-
conjugated anti-mouse IgM, IgG H + L, IgG2a, IgG2b, or IgG3 
(Invitrogen, CA, USA) were diluted at a ratio of 1:1,000. The 
plates were developed with 0.5 mg/mL ortho-phenylenediamine 
(Sigma, MO, USA) in 0.1 M citrate buffer (pH 5.6) containing 
0.08% H2O2 (Sigma, MO, USA). The reaction was stopped with 
1.25 M H2SO4, and the optical densities were read at 492 nm using 
an automatic ELISA plate reader (Multiskan Ascent, Thermo 
Scientific, Vantaa, Finland). The cutoff value was defined as 
threefold above the mean values of the negative controls.
High-avidity IgG antibodies were measured including a wash 
with a mild-denaturing agent to discriminate low-avidity antibod-
ies, which are more likely to dissociate from the antigen–antibody 
complexes (30). Briefly, ELISA was performed as described above 
including a 10 min wash with 7 M urea solution after incubation 
of sera and before the addition of the secondary antibody.
hemagglutination inhibition assay
Sera were treated with receptor destroying enzyme (Denka 
Seiken, Tokyo, Japan) for 19 h at 37°C, according to the manu-
facturer’s instructions. Sera were serially diluted twofold in PBS 
using V-bottom plates (Nunc, Roskilde, Denmark). Diluted sera 
were incubated 30 min at RT with 8 HAU/25 μL of a pandemic 
influenza virus strain A/México/4482/2009 (H1N1). After incu-
bation, 0.5% of chicken red blood cells were added to the plates 
and incubated 30  min at RT. The hemagglutination inhibition 
titer was established as the highest dilution of sera where hemag-
glutination was completely inhibited.
statistical analysis
Statistical analysis was performed with GraphPad Prism 6.0 
(GraphPad Software, La Jolla, CA, USA) applying one-way analy-
sis of variance test with Bonferroni’s multiple comparison cor-
rection. P-values < 0.05 were considered significant. Significant 
differences are depicted as *P < 0.05, **P < 0.01, and ***P < 0.001.
resUlTs
Ompc and OmpF from S. Typhi are 
effective adjuvants for Promoting 
antibody responses to OVa
To evaluate if major S. Typhi porins, hereafter referred to as porins, 
had an adjuvant effect on OVA antibody responses, we immunized 
BALB/c mice with OVA, OVA + porins, or OVA + proteinase K 
digested porins (PorK). Additionally, we included two groups 
immunized with OVA + alum and OVA + LPS to compare the 
relative effects of major S. Typhi porins to other known adju-
vants. OVA-specific antibody titers were measured at different 
time points after immunization. OVA + porins induced higher 
IgG antibody titers, which remained detectable up to 120 days 
after immunization (Figure  1A), while OVA +  PorK did not 
show an effect over OVA alone. The antibody titers induced by 
OVA + porins were similar to the levels induced by OVA + alum 
or OVA + LPS.
Next, we evaluated the affinity maturation and antibody class 
switching induced by co-immunization with S. Typhi porins at day 
30 p.i. OVA + porins induced high-avidity antibodies compared 
to OVA alone (Figure 1B). Moreover, OVA + porins induced a 
significant response of IgG1, IgG2a, and IgG2b; the responses 
were abrogated when digested porins were used (Figure  1C). 
Antibody class switching and antibody titers induced by porins 
co-immunization were comparable to alum or LPS (Figure 1C).
Because CD4+ T cells cooperate with B cells to promote anti-
body responses (31), we investigated whether the adjuvant effect 
of S. Typhi porins was dependent on CD4+ T cells. Depletion of 
CD4+ T cells resulted in the complete abrogation of the antibody 
responses to OVA in the S. Typhi porins co-immunized group 
(Figure  1D), suggesting that CD4+ T  cells are necessary for 
the adjuvant effect induced by S. Typhi porins on the antibody 
responses to OVA.
Altogether, these results suggest that S. Typhi porins can pro-
mote antibody responses to poorly immunogenic model antigens 
such as OVA, in a manner dependent on CD4+ T cell cooperation.
S. Typhi Porins can increase OVa-specific 
cD4+ T cell Proliferation and Th1/Th17 
cytokine Production
Because we observed that the adjuvant effect of S. Typhi porins 
on antibody responses to OVA was dependent on CD4+ T cells, 
we examined if S. Typhi porins could also have an effect on OVA-
specific CD4+ T  cells. CD4+ T  cells from DO.11.10 mice were 
FigUre 1 | Ompc and OmpF from S. Typhi promote antibody responses to ovalbumin (OVa). Four BALB/c mice per group were immunized i.p. with 
100 μg of OVA, OVA + 10 μg of porins, OVA + 10 μg of PorK, OVA + 5 μg of LPS, or OVA + 100 μg of alum. (a) Total IgG antibody responses were measured at 
the indicated time points by ELISA (B) high-avidity IgG and (c) IgG1, IgG2a, and IgG2b were measured at day 30 post-immunization. (D) BALB/c mice were 
injected i.p. with a depleting anti-CD4 mAb (GK1.5) 3 days prior to immunization with OVA or OVA + porins. GK1.5 mAb was given every 3 days thereafter until day 
20, and the serum IgG and IgM responses were measured by ELISA. Mean + SEM are shown. These data are representative of three independent experiments. 
Statistical analysis was performed using one-way ANOVA with Bonferroni test post hoc. For panel (a), Student’s t-test was performed comparing only OVA versus 
OVA + porins groups. Statistical differences are depicted as *P < 0.05, **P < 0.01, ***P < 0.001.
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CFSE labeled and adoptively transferred prior to immunization 
with OVA plus the different adjuvants. We found enhanced OVA-
specific CD4+ T  cell proliferation in the OVA +  porins group, 
similar to alum or LPS (Figures 2A,B). In contrast, enhanced T cell 
proliferation was not observed with OVA +  PorK. Assessment 
of cytokines produced by CD4+ T cells after S. Typhi porins co-
immunization with OVA showed an increase in IFN-γ, IL-17A, 
and IL-2 (Figure 2C). Indeed, IFN-γ and IL-17A were highest in 
the OVA + porins group, while the OVA and OVA + PorK groups 
had similar cytokine profiles. These results show that S. Typhi 
porins enhance OVA-specific CD4+ T-cell proliferation as well as 
IFN-γ, IL-17A, and IL-2 production.
S. Typhi Porins Promote antibody 
responses to inactivated 2009 Pandemic 
influenza Virus
To evaluate if S. Typhi porins could improve the immune 
response to an experimental vaccine, we co-immunized mice 
with an inactivated pandemic influenza A (H1N1) virus (iIAV) 
plus S. Typhi porins, and we measured the antibody responses 
against influenza virus. We found that the addition of porins 
increased IgG antibody titers to iIAV, to a similar extent as 
alum or LPS, and that the response was maintained up to 
120 days post-immunization (Figure 3A), with IgG1 being the 
most readily detectable isotype (Figure  3B). Additionally, we 
found an increase in high-avidity IgG titers (Figure 3C). A key 
element of any vaccine response is to enhance the protection 
afforded by immunization. Therefore, we examined the ability 
of the induced antibodies to promote agglutination of the virus. 
We found that the iIAV +  porins group had higher titers of 
anti-hemagglutinin antibodies (Figure 3D) compared to iIAV 
and iIAV + alum and similar levels to the iIAV + LPS group. 
Together, these results show that S. Typhi porins can potentiate 
functional antibody responses to an experimental pathogen-
derived vaccine.
S. Typhi Porins Promote antibody 
responses to the T-independent  
anti-Typhoid Vi antigen
Because porins can induce T-dependent and T-independent 
responses (32), we examined if they could improve the immune 
response to a T-independent type 2 (TI-2) vaccine antigen. Mice 
FigUre 2 | Porins from S. Typhi increase cell proliferation and Th1/Th17 cytokine production by ovalbumin (OVa)-specific cD4+ T cells. A total of 
5 × 106 CFSE-labeled CD4+ T cells from DO.11.10 mice were transferred to naïve BALB/c mice (4 mice per group) 24 h prior to s.c. injection into the front footpads 
with 100 μg of OVA, OVA + 10 μg of porins, OVA + 10 μg of PorK, OVA + 5 μg of LPS, or OVA + 100 μg of alum. Three days later, in vivo proliferation was 
assessed as frequency of OVA-specific cells (K1-J26+ cells) (a) and CFSE dilution (B). (c) Coculture of purified CD4+ T cells from immunized DO.11.10 BALB/c 
chimeras with OVA-pulsed dendritic cells was performed, supernatants were collected 24 h later, and cytokines were measured by CBA assay. Mean + SEM are 
shown. These data are representative of three independent experiments. Statistical analysis was performed using one-way ANOVA with Bonferroni test post hoc. 
Statistical differences are depicted as *P < 0.05, **P < 0.01, ***P < 0.001.
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were co-immunized with porins and the unconjugated CPS 
Typhim Vi vaccine, and the antibody responses against Vi CPS 
were evaluated. The addition of porins resulted in a fourfold 
increase in IgM and total IgG antibody titers compared to Vi 
CPS alone (Figure  4A). Surprisingly, co-immunization with 
S. Typhi porins only induced higher levels of both IgG1 and 
T-independent associated IgG3 isotype (Figure 4B). These effects 
of porins on the anti-Vi response were lost following the digestion 
of porins. Therefore, porins can improve the antibody responses 
to a TI-2 vaccine antigen.
DiscUssiOn
Vaccination is one of the most efficient strategies to control infec-
tious diseases. Whole inactivated microorganism-based vaccines 
are highly immunogenic; however, they frequently induce unde-
sired side effects. To diminish this possibility, the development of 
vaccines has shifted toward the use of purified antigens. However, 
this strategy carries disadvantages, such as poor immunogenicity 
of the purified antigen (33). To overcome this problem, the use of 
adjuvants has been required to potentiate the immune response 
FigUre 3 | S. Typhi porins enhance functional antibody responses to an inactivated 2009 pandemic influenza vaccine. Four BALB/c mice per group 
were immunized i.p. with 4 HAU of a pandemic inactivated influenza A virus (iIAV), iIAV + 10 μg of porins, iIAV + 10 μg of PorK, iIAV + 5 μg of LPS, or iIAV + 100 μg 
of alum. (a) Serum IgG antibody responses were measured at the indicated time points. (B) IgG1 and IgG2b, high-avidity IgG titers (c) and HI titers (D) were 
measured 30 days post-immunization by ELISA. Mean + SEM are plotted. These data are representative of three independent experiments. Statistical analysis was 
performed using one-way ANOVA with Bonferroni test post hoc. For panel (a), Student’s t-test was performed comparing only ovalbumin (OVA) versus 
OVA + porins groups. Statistical differences are depicted as *P < 0.05, **P < 0.01, ***P < 0.001.
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elicited by vaccination. Although increasing the magnitude of the 
immune response is essential for an adjuvant, the diversification 
and persistence of the response are other factors that should also 
be considered in the development of adjuvants to improve vac-
cine function (34).
Pattern recognition receptor activation of innate immune cells 
by adjuvants contributes to their function (35). Our previous 
studies have shown that S. Typhi porins can efficiently activate 
APCs and induce the expression of costimulatory molecules and 
cytokine production through TLR2, TLR4, and MyD88 signaling 
(12, 14). While minor S. Typhi porins possess adjuvant properties 
(14), the adjuvant potential of OmpC and OmpF porins has not 
been previously assessed.
S. Typhi porins enhanced the anti-OVA IgG antibody 
responses, which is otherwise a poorly immunogenic antigen, to 
a level comparable the antibody response seen when alum or LPS 
FigUre 4 | S. Typhi porins promote antibody responses to the 
T-independent anti-typhoid Vi antigen. Four BALB/c mice per group were 
immunized i.p. with 10 μg of Vi CPS vaccine (Typhim), Vi + 10 μg porins or 
Vi + 10 μg of PorK on days 0 and 15. (a) IgM and total IgG responses and 
(B) IgG1 and IgG3 responses against Vi CPS were measured by ELISA on 
day 20 post-immunization. Mean + SEM are plotted. These data are 
representative of two independent experiments. Statistical analysis was 
performed using one-way ANOVA with Bonferroni test post hoc. Statistical 
differences are depicted as *P < 0.05, **P < 0.01, ***P < 0.001.
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were added. Other porins have also shown an adjuvant effect on 
OVA antibody responses (8, 14, 36), although the persistence of 
this response has not been well examined in most of these stud-
ies. A persistent antibody response lasting several years has been 
shown in humans after immunization with porins (37). Further 
studies are needed to examine the nature of this persistent 
response.
Because long-lasting antibody responses and class switching 
toward IgG1, IgG2a, and IgG2b are associated with an involve-
ment of T-cells (38) and because we observed that the adjuvant 
effect of S. Typhi porins was abrogated after treatment with an 
anti-CD4 monoclonal antibody, we analyzed how porins modified 
T-cell responses. We found that porins enhanced proliferation of 
OVA-specific CD4+ T cells. In addition, porins co-immunization 
promoted the production of IFN-γ, IL-17A, and IL-2 CD4+ T cells. 
This Th1/Th17-associated profile differs from the mixed Th1/Th2 
response to the neisserial porin PorB, although this response was 
only examined in serum (15). Therefore, porins may be useful 
to modulate the immune response toward a Th1 or Th17 profile, 
and this property could be useful for vaccines that require Th1 
responses to induce protection, such as Mycobacterium tuber-
culosis or Chlamydia trachomatis vaccines (39, 40). In addition, 
S. Typhi porins may enhance responses to vaccines where IL-17 
responses are required. Other molecules can also have a Th1/
Th17 promoting effect including CpG (41), poly I:C (42), and 
glucopyranosyl lipid adjuvant-stable emulsion (GLA-SE) (43) 
as well as Borrelia burgdorferi outer surface protein A (44) and 
Brucella abortus outer membrane protein 19 (45).
Porins had a remarkable effect on the response to the inacti-
vated pandemic influenza virus H1N1 2009. Other TLR agonists 
with adjuvant properties, such as CpG (46), Pam3CSK4 (47), and 
GLA-SE (48), have been shown to improve the immunogenicity 
of inactivated influenza vaccines. Interestingly, the induction 
of HIA titers when major S. Typhi porins were included as an 
adjuvant was superior to the effect induced by alum, supporting 
the concept that it is not optimal to increase anti-influenza HIA 
titers (47).
Capsular polysaccharides (CPS), such as S. Typhi Vi, are TI-2 
antigens and are B1b antigens in mice (49). Vaccination with such 
antigens elicits mainly IgM with limited class switching, affinity 
maturation, and immunological memory (50). Currently, most 
vaccines based on CPS perform well in healthy adults but have 
low immunogenicity in infants (51). The Vi CPS vaccine does not 
induce long-lasting immunity beyond 2 years (52). To overcome 
such a disadvantage, CPS are typically conjugated to a carrier 
protein to elicit T-cells and promote IgG switching and memory 
induction (52, 53).
Salmonella Typhi porins could enhance antibody responses 
to the purified, unconjugated Vi CPS, reflecting a similar find-
ing when minor porins are used (14). Other antigens can also 
promote IgG responses, including PLc from Vibrio cholerae (54) 
and other bacterially derived antigens (55). Therefore, the pres-
ence of bacterial antigens may naturally augment such responses, 
possibly by adsorbing the Vi antigen. Porins can induce protective 
B1b antibody responses to Salmonella (32), and because Vi is also 
a B1b antigen (49), these effects could be a consequence of the 
stimulation of B1b cells by porins and Vi antigen. Thus, porins 
could be used as an adjuvant for TI-2 antigens, such as bacterial 
capsular polysaccharides.
The mechanism mediating the adjuvant effect might be related 
to the agonist effect of S. Typhi porins on TLR2 and TLR4 (Figure 
S1 in Supplementary Material). The activation of these receptors 
by porins might mediate the activation of APCs, such as DCs and 
macrophages. Activation of APCs then would induce the expres-
sion of costimulatory molecules and class II MHC expression 
and increase antigen presentation, as has been observed in DCs 
after stimulation or injection with porins (12, 14). It could also 
promote the secretion of pro-inflammatory cytokines, which in 
turn might activate additional cell populations, including T cells 
and B  cells. Nevertheless, the effects of porins in B  cells as a 
consequence of direct ligation of TLRs in these cells cannot be 
discarded, since in a previous report we showed that TLRs on 
B cells importantly contribute in shaping the antibody responses 
against porins (12).
Overall, our observations revealed that the adjuvant effect of 
major S. Typhi porins displayed two patterns. The first pattern 
indicated that the magnitude and diversity of the response were 
augmented similar to the model antigen OVA. The second pattern 
indicated that the diversity of the response elicited by the antigen 
alone remained unchanged but the magnitude of the response 
was augmented. This finding could mean that the mechanism 
underlying the adjuvant effect of porins might vary depending 
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on the antigen that is co-immunized. This possibility should be 
explored further.
The adjuvant effect of porins is similar when compared to 
LPS; however, LPS cannot be used as adjuvant in animals and 
human vaccines due to its high toxicity. Contrary to LPS, we have 
previously shown that porins immunization is safe and well toler-
ated both for mice and humans (25, 27, 28); porins, therefore, 
represent an interesting alternative molecule that can mimic the 
adjuvant effect of LPS without carrying the same toxicity. Porins 
also induce, in terms of magnitude and duration of the response, a 
similar adjuvant effect than alum (the only worldwide used adju-
vant in human vaccines). However, when comparing the features 
of the response induced by porins and alum, some differences 
can be spotted. For example, in DO.11.10 mice, immunization of 
porins is more efficient for driving IFN-γ and IL-17A-mediated 
T  cell responses than alum. Likewise, porins induced higher 
hemagglutination-inhibiting antibody titers than alum when 
used as adjuvant for influenza virus immunization. Besides, we 
showed that porins potentiated the antibody responses against 
an unconjugated, Vi capsular polysaccharide vaccine, whereas 
alum has shown poor adjuvanticity when used to boost antibody 
responses against T-independent antigens (56). Taken together, 
we showed that porins induced a potent adjuvant effect similar to 
the induced by other well-known molecules with adjuvant prop-
erties such as LPS and alum. These results contribute to expand 
the knowledge about new choices of novel molecules that could 
be employed to improve vaccines or to develop new ones.
In conclusion, our results show that major S. Typhi porins 
OmpC and OmpF have adjuvant properties and potentiate, 
diversify, and extend B-cell responses to a diverse repertoire 
of antigens. They function in a manner associated with a Th1/
Th17 profile. Our findings suggest that S. Typhi porins represent 
an additional choice of vaccine adjuvant for T-dependent and 
T-independent antigens.
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